WFH NETWORK

Presentations for the 9th WFH Global Forum on Research and Treatment Products for Bleeding Disorders 

October 22-23, 2015

THURSDAY, OCTOBER 22
TREATMENT PRODUCTS FOR BLEEDING DISORDERS


Safety, supply and access to treatment products


Albert Farrugia, University of Western Australia

Blood safety and availability – current and emerging issues. Presentation
 
William Murphy, Irish Blood Transfusion Service, Ireland
Impact of MSM donor deferrals on safety and supply. Presentation

Marijke van den Berg, University Hospital of Utrecht, Netherlands
EMA guidelines on transparency for clinical trials. Presentation

Albert Farrugia, University of Western Australia
Barriers to access in the developing world. Presentation

Kathleen Rowe, Blood Centers of America (BCA), USA
The changing economics of blood collection. Presentation

Brian O’Mahony, Irish Haemophilia Society, Ireland
Tender & procurement – challenges and opportunities. Presentation

Assad Haffar, World Federation of Hemophilia (WFH)
Expansion of the WFH Humanitarian Aid program. Presentation

Alfonso Iorio, McMaster University, Canada
How to measure progress in the provision of care for hemophilia. Presentation
 
Mark Brooker, World Federation of Hemophilia (WFH)
Inclusion of DDAVP on WHO Essential Medicines List and implications for access. Presentation

Magdy El Ekiaby, Shabrawishi Hospital, Egypt
Outcomes of low-dose prophylaxis in children. Presentation

Inhibitor development: update on surveillance data and analysis


Anneliese Hilger, Paul-Ehrlich-Institut, Germany

Report on the EMA workshop on hemophilia registries. Presentation 

Mike Soucie, Centers for Disease Control and Prevention (CDC), USA
Surveillance for inhibitors in the US. Presentation

Glenn Pierce, Board of Directors, World Federation of Hemophilia (WFH)
Report on FDA inhibitor workshop. Presentation


FRIDAY, OCTOBER 23
RESEARCH


Novel developments in treatment of bleeding disorders


Midori Shima, Nara Medical University, Japan
Factor VIII mimetics. Presentation not available

Gary Gilbert, Harvard Medical School, USA
Non-factor replacement strategies: anti-coagulant inhibition. Presentation

Manuel Carcao, The Hospital for Sick Children, Canada
Prolonged-half life products; current clinical practices. Presentation

Edward Tuddenham, Katharine Dormandy Haemophilia Centre, UK
Gene therapy update. Presentation

Gene therapy for hemophilia – future scenarios for cost, capacity, and impact on FVIII therapy


Mark Skinner, National Hemophilia Foundation, USA
What is a cure worth? Presentation

Glenn Pierce, Board of Directors, World Federation of Hemophilia (WFH)
Gene therapy clinical development and pricing considerations. Presentation

Alok Srivastava, Christian Medical College, India
WFH epidemiological research program. Presentation not available

Updates from WFH clinical research grant recipients


Sébastien Lobet, Cliniques Universitaires St-Luc, Belgium
Quantifying foot biomechanics in hemophilic children. Presentation not available

Lize van Vulpen, UMC Utrecht, Netherlands
Joint distraction in the treatment of hemophilic ankle arthropathy. Presentation

Manufacturers updates


Presentations not available


Updated November 2015